心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

稳定性冠心病基层合理用药指南

2021-04-06 中华医学会心血管病学分会 中华全科医师杂志

冠心病

稳定性冠心病包括3种情况:慢性稳定性劳力型心绞痛、缺血性心肌病和急性冠状动脉综合征(ACS)之后稳定的病程阶段。慢性稳定性劳力型心绞痛是在冠状动脉固定性严重狭窄基础上,由于心肌负荷的增加引

中文标题：

稳定性冠心病基层合理用药指南

发布机构：

中华医学会心血管病学分会

发布日期：

2021-04-06

简要介绍：

稳定性冠心病包括3种情况:慢性稳定性劳力型心绞痛、缺血性心肌病和急性冠状动脉综合征(ACS)之后稳定的病程阶段。慢性稳定性劳力型心绞痛是在冠状动脉固定性严重狭窄基础上,由于心肌负荷的增加引起的心肌急剧的、短暂的缺血缺氧临床综合征。缺血性心肌病指由于长期心肌缺血导致心肌局限性或弥漫性纤维化,从而产生心脏收缩和/或舒张功能受损,引起心脏扩大或僵硬、慢性心力衰竭、心律失常等一系列临床表现的临床综合征。

下载附件：
点击下载

(因为版权问题，不支持下载)

评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2102149, encodeId=0c11210214937, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:30:13 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102147, encodeId=4958210214ea3, content=总结的很好<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:59 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102146, encodeId=55802102146cd, content=很棒<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:42 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102145, encodeId=8384210214555, content=学习了<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:34 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201369, encodeId=83dc120136961, content=<a href='/topic/show?id=c949e5299ed' target=_blank style='color:#2F92EE;'>#稳定性冠心病#</a><a href='/topic/show?id=09ba4194471' target=_blank style='color:#2F92EE;'>#基层#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75299, encryptionId=c949e5299ed, topicName=稳定性冠心病), TopicDto(id=41944, encryptionId=09ba4194471, topicName=基层)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Thu Mar 10 14:55:17 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2022-11-23 ms1000000686260508

    #Nat#很好

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2102149, encodeId=0c11210214937, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:30:13 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102147, encodeId=4958210214ea3, content=总结的很好<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:59 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102146, encodeId=55802102146cd, content=很棒<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:42 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102145, encodeId=8384210214555, content=学习了<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:34 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201369, encodeId=83dc120136961, content=<a href='/topic/show?id=c949e5299ed' target=_blank style='color:#2F92EE;'>#稳定性冠心病#</a><a href='/topic/show?id=09ba4194471' target=_blank style='color:#2F92EE;'>#基层#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75299, encryptionId=c949e5299ed, topicName=稳定性冠心病), TopicDto(id=41944, encryptionId=09ba4194471, topicName=基层)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Thu Mar 10 14:55:17 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2022-11-23 ms1000000686260508

    总结的很好#Cell#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2102149, encodeId=0c11210214937, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:30:13 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102147, encodeId=4958210214ea3, content=总结的很好<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:59 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102146, encodeId=55802102146cd, content=很棒<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:42 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102145, encodeId=8384210214555, content=学习了<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:34 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201369, encodeId=83dc120136961, content=<a href='/topic/show?id=c949e5299ed' target=_blank style='color:#2F92EE;'>#稳定性冠心病#</a><a href='/topic/show?id=09ba4194471' target=_blank style='color:#2F92EE;'>#基层#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75299, encryptionId=c949e5299ed, topicName=稳定性冠心病), TopicDto(id=41944, encryptionId=09ba4194471, topicName=基层)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Thu Mar 10 14:55:17 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2022-11-23 ms1000000686260508

    很棒#期刊论坛#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2102149, encodeId=0c11210214937, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:30:13 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102147, encodeId=4958210214ea3, content=总结的很好<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:59 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102146, encodeId=55802102146cd, content=很棒<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:42 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102145, encodeId=8384210214555, content=学习了<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:34 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201369, encodeId=83dc120136961, content=<a href='/topic/show?id=c949e5299ed' target=_blank style='color:#2F92EE;'>#稳定性冠心病#</a><a href='/topic/show?id=09ba4194471' target=_blank style='color:#2F92EE;'>#基层#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75299, encryptionId=c949e5299ed, topicName=稳定性冠心病), TopicDto(id=41944, encryptionId=09ba4194471, topicName=基层)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Thu Mar 10 14:55:17 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2022-11-23 ms1000000686260508

    学习了#BET#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2102149, encodeId=0c11210214937, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:30:13 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102147, encodeId=4958210214ea3, content=总结的很好<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:59 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102146, encodeId=55802102146cd, content=很棒<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:42 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2102145, encodeId=8384210214555, content=学习了<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2c975456358, createdName=ms1000000686260508, createdTime=Wed Nov 23 10:29:34 CST 2022, time=2022-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201369, encodeId=83dc120136961, content=<a href='/topic/show?id=c949e5299ed' target=_blank style='color:#2F92EE;'>#稳定性冠心病#</a><a href='/topic/show?id=09ba4194471' target=_blank style='color:#2F92EE;'>#基层#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75299, encryptionId=c949e5299ed, topicName=稳定性冠心病), TopicDto(id=41944, encryptionId=09ba4194471, topicName=基层)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=医者仁者, createdTime=Thu Mar 10 14:55:17 CST 2022, time=2022-03-10, status=1, ipAttribution=)]
    2022-03-10 医者仁者

    #稳定性冠心病##基层#

    0

相关指南

冠心病合理用药指南(第2版)

国家卫生计生委合理用药专家委员会 · 2018-03-01

冠心病双联抗血小板治疗中国专家共识

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2021-05-28

2021 ACR适宜性标准：无症状冠心病高危患者

美国放射学会(ACR,American College of Radiology) · 2021-05-18

中成药治疗冠心病临床应用指南（2020年）

暂未更新 · 2021-05-15

2021 SCCT专家共识文件：心血管CT在冠心病职业健康评估中的作用

美国心血管计算机断层扫描学会(SCCT,Society of Cardiovascular Computed Tomography) · 2021-04-20

冠心病心脏康复基层合理用药指南

中华医学会(CMA,Chinese Medical Association) · 2021-03-25

拓展阅读

2016 ACC/AHA指南：冠心病患者双抗治疗持续时间（更新）

美国心脏病学会(ACC,American College of Cardiology) · 2016-03-30

2015 冠心病患者运动治疗中国专家共识

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2016-04-27

2015 AHA/ACC/ASH 冠心病患者高血压治疗的科学声明

美国心脏病学会(ACC,American College of Cardiology) · 2015-03-30

2016 冠心病合理用药指南

暂未更新 · 2016-06-30

2016 高龄老年冠心病诊治中国专家共识

中华医学会老年医学分会 · 2016-07-30

冠心病血瘀证诊断标准

暂未更新 · 2016-10-30